
David Auerbach
@davidiauerbach
Health Economist, dad, game player, hiker, cycler, and classical music enthusiast.
ID: 462289331
12-01-2012 19:55:38
1,1K Tweet
461 Followers
343 Following


New in HSR: "Requiem for Odds Ratios" with Bryan Dowd, Melissa Garrido, and Matt Maciejewski. onlinelibrary.wiley.com/toc/14756773/0⦠We commend HSR for discouraging the reporting of odds ratios in most studies. We agree wholeheartedly with this decision, which keeps HSR at the forefront.


ā¦Adam Cifuā© kindly published my comment to the new but opposing recommendations on breast screening of women in their 40ās from ā¦USPSTFā© and ā¦CTFPHC | GECSSPā©. Progress in treatment deserve more praise for lower bc mortality in this group. sensible-med.com/p/should-womenā¦









If you see an observational study where the drug works immediately for a disease that takes years to develop, throw the study out. Like this study claiming Ozempic reduces risks of Alzheimerās in diabetics within 30 days of initiation. Junk science alz-journals.onlinelibrary.wiley.com/doi/10.1002/alā¦



The Trump admin appears poised to double down on one of Washingtonās most entrenched orthodoxies: value-based payment (VBP) and its ideology of managed care. Andrew Ryan and I argue this is a mistake. Itās time for a new agenda in Medicare. 1/x


Two-part article in Health Affairs Forefront with my thoughts on improving risk adjustment Actually more of a synthesis of great work and insights from the field and a set of recommendations that follows from considering it all together. This is an area where academia/health

